Short Interest in OSR Holdings, Inc. (NASDAQ:OSRH) Drops By 38.1%

OSR Holdings, Inc. (NASDAQ:OSRH) saw a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 1,048,980 shares, a drop of 38.1% from the July 15th total of 1,693,343 shares. Approximately 4.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 705,294 shares, the short-interest ratio is currently 1.5 days.

Hedge Funds Weigh In On OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP acquired a new stake in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned approximately 0.37% of OSR at the end of the most recent quarter. Hedge funds and other institutional investors own 55.30% of the company’s stock.

OSR Trading Down 27.3%

Shares of NASDAQ:OSRH traded down $0.16 during trading on Tuesday, reaching $0.43. The company had a trading volume of 132,069,062 shares, compared to its average volume of 6,452,790. The company has a fifty day moving average of $0.39 and a two-hundred day moving average of $0.47. The stock has a market capitalization of $15.07 million, a P/E ratio of -1.29 and a beta of 0.55. OSR has a 12 month low of $0.25 and a 12 month high of $1.24.

OSR (NASDAQ:OSRH) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter. OSR had a negative return on equity of 8.28% and a negative net margin of 593.15%.The company had revenue of $0.32 million for the quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on OSRH shares. Wall Street Zen upgraded OSR from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.